Barclays analyst Gena Wang lowered the firm’s price target on 4D Molecular (FDMT) to $33 from $38 and keeps an Overweight rating on the shares. The firm views the company’s Q3 update as “largely incremental.” The Otsuka deal and equity offering extend 4D’s cash runway to the second half of 2028, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular Therapeutics Reports Strategic Gains in Q3 2025
- 4D Molecular sees cash runway into 2H28
- 4D Molecular reports Q3 EPS ($1.01), consensus (98c)
- 4D Molecular Therapeutics Closes $93.3 Million Stock Offering
- Bullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Long-term Efficacy, Safety, and Financial Strength Justify Buy Rating